Key facts
- It has raised $77.2M; the latest was Accelerator/Incubator in Jan 2025.
- Notable investors include AWS Startups, Harvard Innovation Launch Lab, Fifty Years, S32, Horizons Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Manifold Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Manifold Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Manifold Bio
Developer of a high-throughput in vivo discovery engine designed to support tissue-specific drug development through AI-guided biologic design. The company offers molecular tracking tools, in vivo measurement capabilities, and a generative modeling framework, enabling researchers focused on neurological and metabolic conditions to design precise therapeutics.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 49
- Website
- manifold.bio/
- Ownership
- Privately Held (backing)
Manifold Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Manifold Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Manifold Bio in its N-PORT filings yet. We sweep new filings monthly.